Oncology Adjuvants Market Analysis

  • Report ID: 5860
  • Published Date: Sep 16, 2025
  • Report Format: PDF, PPT

Oncology Adjuvants Market Segmentation:

Indication Segment Analysis

Based on indication, the breast cancer segment is predicted to account for 15% share of the global oncology adjuvants market during the forecast period. The growth of this segment can be attributed to the back of increasing prevalence of breast cancer. As per data generated by WHO, in 2020 around 2.3 million women were diagnosed with breast cancer and 685000 individuals lost their life due to this disease. Breast cancer is one of the foremost common sorts of cancer among ladies all-inclusive, and adjuvant treatments play a vital part in overseeing and treating this malady. Adjuvant treatments in breast cancer are utilized after essential treatment, regularly including surgery to evacuate the tumor. The essential objective of adjuvant treatments in breast cancer is to decrease the hazard of cancer repeat and make strides in long-term survival rates. They are managed to target any remaining cancer cells that will not have been killed by surgery and to anticipate the spread of cancer cells to other parts of the body. 

End User Segment Analysis

In terms of end user, the cancer hospital segment is predicted to account for 80% share of the global oncology adjuvants market by 2035. Market growth is expected to be driven by increasing demand for cancer hospitals around the world.  Lung cancer, colon cancer, prostate cancer, breast cancer, and other forms of gynecological cancers are treated in cancer hospitals. It helps to reduce the recurrence of cancer by treating it effectively. By increasing the effectiveness of primary therapy, cancer hospitals have been increasingly using this approach in improving patient outcomes. In order to improve the overall effectiveness of therapy, it is used. Market growth is also expected to be driven by increased funding for cancer research and an increase in the incidence of cancer around the world. The product is typically a drug that is used along with primary cancer treatments such as radiation therapy, surgery, and chemotherapy. In the coming years, these factors are expected to accelerate market developments.

Our in-depth analysis of the global market includes the following segments:

         Application

  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  •  Hormone Therapy
  •  Targeted Therapy

         Indication

  • Sarcoma
  • Breast Cancer
  •  Colorectal Cancer
  •  Glioblastoma
  • Prostate Cancer
  • Lung Cancer
  • Ovarian Cancer

          End User

  • Cancer Research Institute
  • Cancer Hospitals

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of oncology adjuvants is evaluated at USD 619.49 million.

The global oncology adjuvants market size was worth over USD 588.76 million in 2025 and is poised to grow at a CAGR of more than 5.8%, reaching USD 1.03 billion revenue by 2035.

North America oncology adjuvants market achieves a 35% share by 2035, driven by rising incidence of cancer, large patient population, and good healthcare facilities.

Key players in the market include Amgen Inc., Bristol Myers Squibb, Eli Lilly and Company, Biogen AstraZeneca plc, Pfizer Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd. .
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos